Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC
An Open-label, Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients
Sponsor: GlaxoSmithKline
Listed as NCT04313504, this PHASE2 trial focuses on Head and Neck Cancer and remains ongoing. Sponsored by GlaxoSmithKline, it has been updated 12 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Active Not Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Mar 2023 — Mar 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 7 earlier versions
-
Feb 2023 — Mar 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Nov 2022 — Feb 2023 [monthly]
Recruiting PHASE2
-
Oct 2021 — Nov 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2020 — Dec 2020 [monthly]
Not Yet Recruiting PHASE2
-
Apr 2020 — Jun 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
- Trisha Wise-Draper
For direct contact, visit the study record on ClinicalTrials.gov .